Bev is approved along with chemotherapy in advanced non-squamous NSCLC owing to its antiangiogenic effects, anti–vascular endothelial growth factor (VEGF), and immunomodulatory effects. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.